Ultragenyx
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $40.265
- Today's High:
- $41.6575
- Open Price:
- $40.64
- 52W Low:
- $33.36
- 52W High:
- $54.98
- Prev. Close:
- $40.74
- Volume:
- 798247
Company Statistics
- Market Cap.:
- $2.91 billion
- Book Value:
- 1.806
- Revenue TTM:
- $402.86 million
- Operating Margin TTM:
- -167%
- Gross Profit TTM:
- $-370780000
- Profit Margin:
- -178.91%
- Return on Assets TTM:
- -31.95%
- Return on Equity TTM:
- -178.6%
Company Profile
Ultragenyx had its IPO on 2014-01-31 under the ticker symbol RARE.
The company operates in the Healthcare sector and Biotechnology industry. Ultragenyx has a staff strength of 1,311 employees.
Stock update
Shares of Ultragenyx opened at $40.64 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $40.27 - $41.66, and closed at $41.41.
This is a +1.64% increase from the previous day's closing price.
A total volume of 798,247 shares were traded at the close of the day’s session.
In the last one week, shares of Ultragenyx have increased by +9.61%.
Ultragenyx's Key Ratios
Ultragenyx has a market cap of $2.91 billion, indicating a price to book ratio of 6.7978 and a price to sales ratio of 9.304.
In the last 12-months Ultragenyx’s revenue was $402.86 million with a gross profit of $-370780000 and an EBITDA of $-652508032. The EBITDA ratio measures Ultragenyx's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ultragenyx’s operating margin was -167% while its return on assets stood at -31.95% with a return of equity of -178.6%.
In Q2, Ultragenyx’s quarterly earnings growth was a positive 0% while revenue growth was a positive 21.2%.
Ultragenyx’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.24
Its diluted EPS in the last 12-months stands at $-10.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.24. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ultragenyx’s profitability.
Ultragenyx stock is trading at a EV to sales ratio of 6.7945 and a EV to EBITDA ratio of -3.744. Its price to sales ratio in the trailing 12-months stood at 9.304.
Ultragenyx stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.31 billion
- Total Liabilities
- $244.38 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $16.44 million
- Dividend Payout Ratio
- 0%
Ultragenyx ended 2024 with $1.31 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.31 billion while shareholder equity stood at $129.03 million.
Ultragenyx ended 2024 with $0 in deferred long-term liabilities, $244.38 million in other current liabilities, 71000.00 in common stock, $-3104822000.00 in retained earnings and $44.41 million in goodwill. Its cash balance stood at $102.06 million and cash and short-term investments were $551.98 million. The company’s total short-term debt was $10,884,000 while long-term debt stood at $0.
Ultragenyx’s total current assets stands at $702.14 million while long-term investments were $71.83 million and short-term investments were $449.92 million. Its net receivables were $70.52 million compared to accounts payable of $42.12 million and inventory worth $28.26 million.
In 2024, Ultragenyx's operating cash flow was $0 while its capital expenditure stood at $16.44 million.
Comparatively, Ultragenyx paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $41.41
- 52-Week High
- $54.98
- 52-Week Low
- $33.36
- Analyst Target Price
- $89.85
Ultragenyx stock is currently trading at $41.41 per share. It touched a 52-week high of $54.98 and a 52-week low of $54.98. Analysts tracking the stock have a 12-month average target price of $89.85.
Its 50-day moving average was $40.29 and 200-day moving average was $43.14 The short ratio stood at 6.58 indicating a short percent outstanding of 0%.
Around 466.5% of the company’s stock are held by insiders while 9857.9% are held by institutions.
Frequently Asked Questions About Ultragenyx
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.